Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease

Gene Therapy

Volumn 19, Issue 3, 2012, Pages 264-270

  Niebuhr, A ^a   Henry, T ^b   Goldman, J ^b   Baumgartner, I ^c   Van Belle, E ^d   Gerss, J ^a   Hirsch, A T ^e   Nikol, S ^a,f  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF MINNESOTA   (United States)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

angiogenesis; long term follow up; NV1FGF; peripheral artery disease; registry; safety

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; PLACEBO;

ADULT; AGED; ANGIOGENIC GENE THERAPY; ANGIOPLASTY; ARTICLE; BYPASS SURGERY; COLON CANCER; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB AMPUTATION; LIMB ISCHEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NONVIRAL GENE THERAPY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; REVASCULARIZATION; STROKE;

AGED; AGED, 80 AND OVER; AMPUTATION; FEMALE; FIBROBLAST GROWTH FACTOR 1; FOLLOW-UP STUDIES; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; PERIPHERAL ARTERIAL DISEASE; STROKE; SURVIVAL ANALYSIS;

EID: 84858007033     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.85     Document Type: Article

References (32)

1. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
2. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185-192. (Pubitemid 28277594)
3. Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol 1996; 25: 282-290. (Pubitemid 26137108)
4. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324. (Pubitemid 33015522)
5. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
6. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher CS, Hiatt WR. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group. Circulation 1999; 100: e75-e81.
7. Ouriel K. Peripheral arterial disease. Lancet 2001; 358: 1257-1264. (Pubitemid 33010855)
8. Novo S, Coppola G, Milio G. Critical limb ischemia: definition and natural history. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 219-225. (Pubitemid 39162412)
9. Long-term mortality and its predictors in patients with critical leg ischaemia. The I.C.A.I. Group (Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori). The Study Group of Criticial Chronic Ischemia of the Lower Exremities. Eur J Vasc Endovasc Surg 1997; 14: 91-95.
10. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
11. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-374. (Pubitemid 26261511)
12. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi MC et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16: 972-978. (Pubitemid 351587109)
13. Luther M, Lepantalo M, Alback A, Matzke S. Amputation rates as a measure of vascular surgical results. Br J Surg 1996; 83: 241-244. (Pubitemid 26050152)
14. Brevetti G, Oliva G, Giugliano G, Schiano V, De Maio JI, Chiariello M. Mortality in peripheral arterial disease: a comparison of patients managed by vascular specialists and general practitioners. J Gen Intern Med 2007; 22: 639-644. (Pubitemid 46947947)
15. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31 (1 Part 2): S1-S296.
16. Karnegis JN, Matts JP, Tuna N, Hunter D, Amplatz K. Correlation of coronary with peripheral arterial stenosis. The POSCH Group. Atherosclerosis 1992; 92: 25-30.
17. Atmer B, Jogestrand T, Laska J, Lund F. Peripheral artery disease in patients with coronary artery disease. Int Angiol 1995; 14: 89-93.
18. Dieter RS, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, Einerson J et al. Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Vasc Med 2003; 8: 233-236. (Pubitemid 38585136)
19. Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007; 58: 309-315. (Pubitemid 46956260)
20. Hasimu B, Li J, Nakayama T, Yu J, Yang J, Li X et al. Ankle brachial index as a marker of atherosclerosis in Chinese patients with high cardiovascular risk. Hypertens Res 2006; 29: 23-28.
21. Zheng LQ, Li J, Yu JM, Hasimu B, Hu DY. [Study on the independent association of uric acid levels with peripheral arterial disease in Chinese patients with coronary heart disease]. Zhonghua Liu Xing Bing Xue Za Zhi 2006; 27: 161-164.
22. Schiano V, Brevetti G, Sirico G, Silvestro A, Giugliano G, Chiariello M. Functional status measured by walking impairment questionnaire and cardiovascular risk prediction in peripheral arterial disease: results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. Vasc Med 2006; 11: 147-154. (Pubitemid 46099258)
23. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: REVIEWS3005.
24. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-197.
25. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
26. Snow SG, Calder EA, Taylor LS, Lane TJ, Manu P, Federici CM. Screening for cancer and coronary risk factors through a nurse practitioner-staffed preventive health clinic. Prev Med 1989; 18: 817-823. (Pubitemid 20075626)
27. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni Jr JF. Relation of body mass index to cancer risk in 362552 Swedish men. Cancer Causes Control 2006; 17: 901-909. (Pubitemid 44078281)
28. Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997; 18: 1351-1354. (Pubitemid 28134708)
29. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol 2008; 9: 649-656.
30. Mimoun L, Massin P, Steg G. Retinal microvascularisation abnormalities and cardiovascular risk. Arch Cardiovasc Dis 2009; 102: 449-456.
31. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-936. (Pubitemid 44718562)
32. Baumgartner I, Chronos N, Comerota A, Henry T, Pasquet JP, Finiels F et al. Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009; 17: 914-921.